Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 324

1.

Chromogranin A Analysis in the Differential Diagnosis Across Lewy Body Disorders.

Gmitterova K, Varges D, Schmitz M, Zafar S, Maass F, Lingor P, Zerr I.

J Alzheimers Dis. 2020 Jan 6. doi: 10.3233/JAD-191153. [Epub ahead of print]

PMID:
31929170
2.

Validation of Poly(Propylene Imine) Glycodendrimers Towards Their Anti-prion Conversion Efficiency.

Schmitz M, Candelise N, Kanata E, Llorens F, Thüne K, Villar-Piqué A, da Silva Correia SM, Dafou D, Sklaviadis T, Appelhans D, Zerr I.

Mol Neurobiol. 2019 Dec 17. doi: 10.1007/s12035-019-01837-w. [Epub ahead of print]

PMID:
31848935
3.

Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients.

Zerr I, Villar-Piqué A, Schmitz VE, Poleggi A, Pocchiari M, Sánchez-Valle R, Calero M, Calero O, Baldeiras I, Santana I, Kovacs GG, Llorens F, Schmitz M.

Biomolecules. 2019 Nov 28;9(12). pii: E800. doi: 10.3390/biom9120800.

4.

The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid.

Kranaster L, Hoyer C, Mindt S, Neumaier M, Müller N, Zill P, Schwarz MJ, Moll N, Lutz B, Bindila L, Zerr I, Schmitz M, Blennow K, Zetterberg H, Haffner D, Leifheit-Nestler M, Ozbalci C, Sartorius A.

Eur Arch Psychiatry Clin Neurosci. 2019 Nov 23. doi: 10.1007/s00406-019-01086-x. [Epub ahead of print]

PMID:
31760473
5.

Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson's disease.

Maass F, Michalke B, Willkommen D, Leha A, Schulte C, Tönges L, Mollenhauer B, Trenkwalder C, Rückamp D, Börger M, Zerr I, Bähr M, Lingor P.

Neurobiol Dis. 2020 Feb;134:104677. doi: 10.1016/j.nbd.2019.104677. Epub 2019 Nov 13.

6.

Therapies for prion diseases.

Zafar S, Noor A, Zerr I.

Handb Clin Neurol. 2019;165:47-58. doi: 10.1016/B978-0-444-64012-3.00004-6.

PMID:
31727228
7.

Cerebrospinal fluid neurogranin as a new player in prion disease diagnosis and prognosis.

Villar-Pique A, Zerr I, Llorens F.

Neural Regen Res. 2020 May;15(5):861-862. doi: 10.4103/1673-5374.268901. No abstract available.

8.

Cerebrospinal fluid non-phosphorylated tau in the differential diagnosis of Creutzfeldt-Jakob disease: a comparative prospective study with 14-3-3.

Llorens F, Villar-Piqué A, Hermann P, Schmitz M, Goebel S, Waniek K, Lachmann I, Zerr I.

J Neurol. 2019 Nov 7. doi: 10.1007/s00415-019-09610-8. [Epub ahead of print]

PMID:
31701333
9.

Selenium speciation analysis in the cerebrospinal fluid of patients with Parkinson's disease.

Maass F, Michalke B, Willkommen D, Schulte C, Tönges L, Boerger M, Zerr I, Bähr M, Lingor P.

J Trace Elem Med Biol. 2020 Jan;57:126412. doi: 10.1016/j.jtemb.2019.126412. Epub 2019 Sep 24.

PMID:
31582281
10.

Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry.

Minikel EV, Kuhn E, Cocco AR, Vallabh SM, Hartigan CR, Reidenbach AG, Safar JG, Raymond GJ, McCarthy MD, O'Keefe R, Llorens F, Zerr I, Capellari S, Parchi P, Schreiber SL, Carr SA.

Mol Cell Proteomics. 2019 Dec;18(12):2388-2400. doi: 10.1074/mcp.RA119.001702. Epub 2019 Sep 26.

PMID:
31558565
11.

The cellular prion protein and its derived fragments in human prion diseases and their role as potential biomarkers.

Thüne K, Schmitz M, Villar-Piqué A, Altmeppen HC, Schlomm M, Zafar S, Glatzel M, Llorens F, Zerr I.

Expert Rev Mol Diagn. 2019 Nov;19(11):1007-1018. doi: 10.1080/14737159.2019.1667231. Epub 2019 Sep 26.

PMID:
31512940
12.

A novel V272D presenilin mutation associated with logopenia, disorientation, and apraxia in an autosomal-dominant Alzheimer's disease family.

Mengel D, Liu L, Yamamoto R, Zülow S, Deuschl C, Hermann DM, Zerr I, Selkoe DJ, Dodel R.

Neurobiol Aging. 2020 Jan;85:154.e5-154.e7. doi: 10.1016/j.neurobiolaging.2019.07.002. Epub 2019 Aug 7.

PMID:
31500908
13.

RNA editing alterations define manifestation of prion diseases.

Kanata E, Llorens F, Dafou D, Dimitriadis A, Thüne K, Xanthopoulos K, Bekas N, Espinosa JC, Schmitz M, Marín-Moreno A, Capece V, Shormoni O, Andréoletti O, Bonn S, Torres JM, Ferrer I, Zerr I, Sklaviadis T.

Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19727-19735. doi: 10.1073/pnas.1803521116. Epub 2019 Sep 6.

14.

Tau-protein concentrations are not elevated in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy.

Möhn N, Luo Y, Skripuletz T, Schwenkenbecher P, Zerr I, Lange P, Stangel M.

Fluids Barriers CNS. 2019 Sep 5;16(1):28. doi: 10.1186/s12987-019-0148-3.

15.

Increased expression of heme-binding protein 1 early in Alzheimer's disease is linked to neurotoxicity.

Yagensky O, Kohansal-Nodehi M, Gunaseelan S, Rabe T, Zafar S, Zerr I, Härtig W, Urlaub H, Chua JJ.

Elife. 2019 Aug 27;8. pii: e47498. doi: 10.7554/eLife.47498.

16.

Plasma YKL-40 in the spectrum of neurodegenerative dementia.

Villar-Piqué A, Schmitz M, Hermann P, Goebel S, Bunck T, Varges D, Ferrer I, Riggert J, Llorens F, Zerr I.

J Neuroinflammation. 2019 Jul 12;16(1):145. doi: 10.1186/s12974-019-1531-3.

17.

Cadmium induces GAPDH- and- MDH mediated delayed cell aging and dysfunction in Candida tropicalis 3Aer.

Khan Z, Nisar MA, Muzammil S, Zafar S, Zerr I, Rehman A.

Environ Monit Assess. 2019 Jul 11;191(8):490. doi: 10.1007/s10661-019-7631-9.

PMID:
31297613
18.

Cytosolic Trapping of a Mitochondrial Heat Shock Protein Is an Early Pathological Event in Synucleinopathies.

Szegő ÉM, Dominguez-Meijide A, Gerhardt E, König A, Koss DJ, Li W, Pinho R, Fahlbusch C, Johnson M, Santos P, Villar-Piqué A, Thom T, Rizzoli S, Schmitz M, Li J, Zerr I, Attems J, Jahn O, Outeiro TF.

Cell Rep. 2019 Jul 2;28(1):65-77.e6. doi: 10.1016/j.celrep.2019.06.009.

19.

Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases.

Llorens F, Villar-Piqué A, Schmitz M, Diaz-Lucena D, Wohlhage M, Hermann P, Goebel S, Schmidt I, Glatzel M, Hauw JJ, Sikorska B, Liberski PP, Riggert J, Ferrer I, Zerr I.

Neuropathol Appl Neurobiol. 2019 Jun 19. doi: 10.1111/nan.12573. [Epub ahead of print]

PMID:
31216593
20.

Age at onset in genetic prion disease and the design of preventive clinical trials.

Minikel EV, Vallabh SM, Orseth MC, Brandel JP, Haïk S, Laplanche JL, Zerr I, Parchi P, Capellari S, Safar J, Kenny J, Fong JC, Takada LT, Ponto C, Hermann P, Knipper T, Stehmann C, Kitamoto T, Ae R, Hamaguchi T, Sanjo N, Tsukamoto T, Mizusawa H, Collins SJ, Chiesa R, Roiter I, de Pedro-Cuesta J, Calero M, Geschwind MD, Yamada M, Nakamura Y, Mead S.

Neurology. 2019 Jul 9;93(2):e125-e134. doi: 10.1212/WNL.0000000000007745. Epub 2019 Jun 6.

PMID:
31171647
21.

CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD.

Blennow K, Diaz-Lucena D, Zetterberg H, Villar-Pique A, Karch A, Vidal E, Hermann P, Schmitz M, Ferrer Abizanda I, Zerr I, Llorens F.

J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):846-853. doi: 10.1136/jnnp-2018-320155. Epub 2019 May 16.

PMID:
31097472
22.

Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development.

Vallabh SM, Nobuhara CK, Llorens F, Zerr I, Parchi P, Capellari S, Kuhn E, Klickstein J, Safar JG, Nery FC, Swoboda KJ, Geschwind MD, Zetterberg H, Arnold SE, Minikel EV, Schreiber SL.

Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7793-7798. doi: 10.1073/pnas.1901947116. Epub 2019 Apr 1.

23.

Seeding variability of different alpha synuclein strains in synucleinopathies.

Candelise N, Schmitz M, Llorens F, Villar-Piqué A, Cramm M, Thom T, da Silva Correia SM, da Cunha JEG, Möbius W, Outeiro TF, Álvarez VG, Banchelli M, D'Andrea C, de Angelis M, Zafar S, Rabano A, Matteini P, Zerr I.

Ann Neurol. 2019 May;85(5):691-703. doi: 10.1002/ana.25446. Epub 2019 Mar 27.

PMID:
30805957
24.

Variably protease-sensitive prionopathy presenting within ALS/FTD spectrum.

Vicente-Pascual M, Rossi M, Gámez J, Lladó A, Valls J, Grau-Rivera O, Ávila Polo R, Llorens F, Zerr I, Ferrer I, Nos C, Parchi P, Sánchez-Valle R, Gelpí E.

Ann Clin Transl Neurol. 2018 Sep 21;5(10):1297-1302. doi: 10.1002/acn3.632. eCollection 2018 Oct.

25.

Distinct microglia profile in Creutzfeldt-Jakob disease and Alzheimer's disease is independent of disease kinetics.

Krbot K, Hermann P, Skorić MK, Zerr I, Sepulveda-Falla D, Goebel S, Matschke J, Krasemann S, Glatzel M.

Neuropathology. 2018 Dec;38(6):591-600. doi: 10.1111/neup.12517. Epub 2018 Oct 15.

PMID:
30318820
26.

Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease.

Kanata E, Golanska E, Villar-Piqué A, Karsanidou A, Dafou D, Xanthopoulos K, Schmitz M, Ferrer I, Karch A, Sikorska B, Liberski PP, Sklaviadis T, Zerr I, Llorens F.

J Clin Neurosci. 2019 Feb;60:124-127. doi: 10.1016/j.jocn.2018.09.031. Epub 2018 Oct 9.

PMID:
30309804
27.

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease.

Kruse N, Heslegrave A, Gupta V, Foiani M, Villar-Piqué A, Schmitz M, Lehmann S, Teunissen C, Blennow K, Zetterberg H, Mollenhauer B, Zerr I, Llorens F.

Alzheimers Dement (Amst). 2018 Jul 7;10:461-470. doi: 10.1016/j.dadm.2018.06.005. eCollection 2018.

28.

Diagnostic challenges in rapidly progressive dementia.

Zerr I, Hermann P.

Expert Rev Neurother. 2018 Oct;18(10):761-772. doi: 10.1080/14737175.2018.1519397. Epub 2018 Sep 17. Review.

PMID:
30173564
29.

Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein.

Albus A, Gold M, Bach JP, Burg-Roderfeld M, Jördens M, Kirchhein Y, Kronimus Y, Mengel D, Zerr I, Dodel R.

PLoS One. 2018 Aug 29;13(8):e0202954. doi: 10.1371/journal.pone.0202954. eCollection 2018.

30.

Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt-Jakob Disease and Synucleinopathy.

Schmitz M, Villar-Piqué A, Llorens F, Gmitterová K, Hermann P, Varges D, Zafar S, Lingor P, Vanderstichele H, Demeyer L, Stoops E, Trojanowski JQ, Lee VM, Zerr I.

Mol Neurobiol. 2019 May;56(5):3476-3483. doi: 10.1007/s12035-018-1313-4. Epub 2018 Aug 22.

PMID:
30136097
31.

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study.

Kranaster L, Hoyer C, Aksay SS, Bumb JM, Müller N, Zill P, Schwarz MJ, Moll N, Lutz B, Bindila L, Zerr I, Schmitz M, Blennow K, Zetterberg H, Haffner D, Leifheit-Nestler M, Ozbalci C, Janke C, Thiel M, Sartorius A.

Neuropsychobiology. 2019;77(1):13-22. doi: 10.1159/000491401. Epub 2018 Aug 17.

PMID:
30121652
32.

Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.

Gmitterová K, Gawinecka J, Llorens F, Varges D, Valkovič P, Zerr I.

Eur Arch Psychiatry Clin Neurosci. 2018 Aug 6. doi: 10.1007/s00406-018-0928-9. [Epub ahead of print]

PMID:
30083957
33.

MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives.

Kanata E, Thüne K, Xanthopoulos K, Ferrer I, Dafou D, Zerr I, Sklaviadis T, Llorens F.

Front Aging Neurosci. 2018 Jul 23;10:220. doi: 10.3389/fnagi.2018.00220. eCollection 2018.

34.

Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases.

Villar-Piqué A, Schmitz M, Lachmann I, Karch A, Calero O, Stehmann C, Sarros S, Ladogana A, Poleggi A, Santana I, Ferrer I, Mitrova E, Žáková D, Pocchiari M, Baldeiras I, Calero M, Collins SJ, Geschwind MD, Sánchez-Valle R, Zerr I, Llorens F.

Mol Neurobiol. 2019 Apr;56(4):2811-2821. doi: 10.1007/s12035-018-1251-1. Epub 2018 Jul 30.

PMID:
30062673
35.

Sporadic Fatal Insomnia in Europe: Phenotypic Features and Diagnostic Challenges.

Abu-Rumeileh S, Redaelli V, Baiardi S, Mackenzie G, Windl O, Ritchie DL, Didato G, Hernandez-Vara J, Rossi M, Capellari S, Imperiale D, Rizzone MG, Belotti A, Sorbi S, Rozemuller AJM, Cortelli P, Gelpi E, Will RG, Zerr I, Giaccone G, Parchi P.

Ann Neurol. 2018 Sep;84(3):347-360. doi: 10.1002/ana.25300. Epub 2018 Aug 31.

PMID:
30048013
36.

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD.

Ermann N, Lewczuk P, Schmitz M, Lange P, Knipper T, Goebel S, Kornhuber J, Zerr I, Llorens F.

Ann Clin Transl Neurol. 2018 May 26;5(7):883-887. doi: 10.1002/acn3.584. eCollection 2018 Jul.

37.

Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance.

Hermann P, Laux M, Glatzel M, Matschke J, Knipper T, Goebel S, Treig J, Schulz-Schaeffer W, Cramm M, Schmitz M, Zerr I.

Neurology. 2018 Jul 24;91(4):e331-e338. doi: 10.1212/WNL.0000000000005860. Epub 2018 Jun 22.

PMID:
29934424
38.

Sporadic Creutzfeldt-Jakob disease.

Zerr I, Parchi P.

Handb Clin Neurol. 2018;153:155-174. doi: 10.1016/B978-0-444-63945-5.00009-X.

PMID:
29887134
39.

Amplification and Detection of Minuscule Amounts of Misfolded Prion Protein by Using the Real-Time Quaking-Induced Conversion.

Schmitz M, Candelise N, Llorens F, Zerr I.

Methods Mol Biol. 2018;1779:257-263. doi: 10.1007/978-1-4939-7816-8_16.

PMID:
29886538
40.

Cerebrospinal Fluid Prion Disease Biomarkers in Pre-clinical and Clinical Naturally Occurring Scrapie.

Llorens F, Barrio T, Correia Â, Villar-Piqué A, Thüne K, Lange P, Badiola JJ, Schmitz M, Lachmann I, Bolea R, Zerr I.

Mol Neurobiol. 2018 Nov;55(11):8586-8591. doi: 10.1007/s12035-018-1014-z. Epub 2018 Mar 23.

PMID:
29572672
41.

Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases.

Villar-Piqué A, Schmitz M, Candelise N, Ventura S, Llorens F, Zerr I.

Mol Neurobiol. 2018 Sep;55(9):7588-7605. doi: 10.1007/s12035-018-0926-y. Epub 2018 Feb 10. Review.

PMID:
29429052
42.

Animal TSEs and public health: What remains of past lessons?

Zafar S, Shafiq M, Andréoletti O, Zerr I.

PLoS Pathog. 2018 Feb 8;14(2):e1006759. doi: 10.1371/journal.ppat.1006759. eCollection 2018 Feb. No abstract available.

43.

Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases.

Zerr I, Schmitz M, Karch A, Villar-Piqué A, Kanata E, Golanska E, Díaz-Lucena D, Karsanidou A, Hermann P, Knipper T, Goebel S, Varges D, Sklaviadis T, Sikorska B, Liberski PP, Santana I, Ferrer I, Zetterberg H, Blennow K, Calero O, Calero M, Ladogana A, Sánchez-Valle R, Baldeiras I, Llorens F.

Alzheimers Dement. 2018 Jun;14(6):751-763. doi: 10.1016/j.jalz.2017.12.008. Epub 2018 Feb 3.

44.

Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson's disease.

Maass F, Michalke B, Leha A, Boerger M, Zerr I, Koch JC, Tönges L, Bähr M, Lingor P.

J Neurochem. 2018 May;145(4):342-351. doi: 10.1111/jnc.14316. Epub 2018 Apr 2.

45.

Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis.

Llorens F, Thüne K, Martí E, Kanata E, Dafou D, Díaz-Lucena D, Vivancos A, Shomroni O, Zafar S, Schmitz M, Michel U, Fernández-Borges N, Andréoletti O, Del Río JA, Díez J, Fischer A, Bonn S, Sklaviadis T, Torres JM, Ferrer I, Zerr I.

PLoS Pathog. 2018 Jan 22;14(1):e1006802. doi: 10.1371/journal.ppat.1006802. eCollection 2018 Jan.

46.

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias.

Llorens F, Thüne K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, Kovatsi E, Pleschka C, Garcia-Esparcia P, Schmitz M, Ozbay D, Correia S, Correia Â, Milosevic I, Andréoletti O, Fernández-Borges N, Vorberg IM, Glatzel M, Sklaviadis T, Torres JM, Krasemann S, Sánchez-Valle R, Ferrer I, Zerr I.

Mol Neurodegener. 2017 Nov 10;12(1):83. doi: 10.1186/s13024-017-0226-4.

47.

Cerebrospinal fluid in Creutzfeldt-Jakob disease.

Zerr I, Zafar S, Schmitz M, Llorens F.

Handb Clin Neurol. 2017;146:115-124. doi: 10.1016/B978-0-12-804279-3.00008-3. Review.

PMID:
29110766
48.

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Lewczuk P, Riederer P, O'Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, Van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J; Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut.

World J Biol Psychiatry. 2018 Jun;19(4):244-328. doi: 10.1080/15622975.2017.1375556. Epub 2017 Oct 27. Review.

49.

DNA versus RNA oxidation in Parkinson's disease: Which is more important?

Gmitterová K, Gawinecka J, Heinemann U, Valkovič P, Zerr I.

Neurosci Lett. 2018 Jan 1;662:22-28. doi: 10.1016/j.neulet.2017.09.048. Epub 2017 Sep 27.

PMID:
28963060
50.

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia.

Llorens F, Schmitz M, Knipper T, Schmidt C, Lange P, Fischer A, Hermann P, Zerr I.

Front Aging Neurosci. 2017 Sep 12;9:289. doi: 10.3389/fnagi.2017.00289. eCollection 2017.

Supplemental Content

Support Center